Onalespib and Paclitaxel in Treating Patients With Advanced Triple Negative Breast Cancer
Status: TERMINATED
Study type: INTERVENTIONAL
Conditions: Advanced Breast Carcinoma|Metastatic Breast Carcinoma|Stage III Breast Cancer AJCC v7|Stage IIIA Breast Cancer AJCC v7|Stage IIIB Breast Cancer AJCC v7|Stage IIIC Breast Cancer AJCC v7|Stage IV Breast Cancer AJCC v6 and v7|Triple-Negative Breast Carcinoma
Interventions: OTHER: Laboratory Biomarker Analysis|DRUG: Onalespib|DRUG: Paclitaxel|OTHER: Pharmacological Study
Sponsor: National Cancer Institute (NCI)